Henry Schein, Inc. (HSIC) vs Entrada Therapeutics, Inc. (TRDA)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| HSIC | TRDA | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Medical Distribution | Biotechnology |
| Size band | MID | SMALL |
| Listing | Nasdaq GS | Nasdaq GM |
| Country | United States | United States |
| Theme | dental-care | rare-disease |
| Price and returns | ||
| Last close | $84.51 | $4.75 |
| Return · 1 week | +0.64% | −1.45% |
| Return · 1 month | −1.72% | −23.63% |
| Return · 3 months | −1.40% | −18.52% |
| Return · year to date | +10.01% | −52.74% |
| Return · 1 year | +33.00% | −35.02% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −8.32% | −71.12% |
| 52-week high | $92.18 | $16.45 |
| 52-week low | $62.15 | $4.11 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $9.63B | $184.95M |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $86.83M | $1.40M |
| Employees | 25,000 | 152 |
| Valuation | ||
| Price to earnings · trailing | 24.77× | n/a (negative earnings) |
| Price to earnings · forward | 14.17× | n/a (negative forward earnings) |
| Price to sales | 0.71× | 36.31× |
| Price to book | 3.01× | 0.68× |
| Enterprise value to EBITDA | 13.60× | n/a (negative enterprise value and EBITDA) |
| Enterprise value to revenue | 1.08× | n/a (negative enterprise value) |
| PEG ratio | 1.69 | — |
| Earnings per share · trailing | 3.43 | -3.96 |
| Profitability | ||
| Gross margin | 31.32% | — |
| Operating margin | 5.76% | −5007.02% |
| Profit margin | 2.96% | −3537.73% |
| Return on equity | 8.85% | −54.10% |
| Return on assets | 4.39% | −29.20% |
| Growth | ||
| Revenue growth | +6.70% | −53.90% |
| Earnings growth | +17.10% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 80.73 | 20.80 |
| Current ratio | 1.32 | 10.89 |
| Dividend yield | 0.00% | 0.00% |
| Payout ratio | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 45.66 | 26.74 |
| ADX · 14 | 18.77 | 33.43 |
| 50-day average | $86.85 | $6.58 |
| 200-day average | $80.89 | $9.05 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.39% | 10.20% |
The full HSIC analysis
Everything this table leaves out for Henry Schein, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the HSIC argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full HSIC analysisThe full TRDA analysis
Everything this table leaves out for Entrada Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the TRDA argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full TRDA analysis